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Background: Ovarian cancer diagnosis is currently based on imaging and circulating CA-125 concentrations with
well-known limits to sensitivity and specificity. New biomarkers are required to complement CA-125 testing to
increase effectiveness. Increases in sensitivity of isotopic separation via multi collector inductively coupled
plasma-mass spectrometry have recently allowed highly accurate measurement of copper (Cu) isotopic varia-
tions. Studies in breast cancer patients have revealed changes of serum copper isotopic composition demon-
strating the potential for development as a cancer biomarker. Evaluating 65Cu/63Cu ratios (δ65Cu) in serum
samples from cancer patients has revealed a strong correlation with cancer development. In this study blood
samples from forty-four ovarian cancer patients, and 13 ovarian biopsies were investigated.
Results: Here we demonstrate that changes in Cu isotopes also occurs in ovarian cancer patients. Copper com-
position determined by multiple collector inductively coupled plasma mass spectrometry revealed that the
copper isotopic ratio δ65Cu in the plasma of 44 ovarian cancer patient cohort was significantly lower than in a
group of 48 healthy donors, and indicated that serum was enriched for 63Cu. Further analysis revealed that the
isotopic composition of tumour biopsies was enriched for 65Cu compared with adjacent healthy ovarian tissues.
Conclusions: We propose that these changes are due to increase lactate and Cu transporter activities in the
tumour. These observations demonstrate that, combined with existing strategies, δ65Cu could be developed for
use in ovarian cancer early detection.
1. Introduction
Copper (Cu) is a vital nutrient absorbed by intestinal cells and
transported to the liver where it is stored thus controlling its con-
centration in blood [1,2]. Cu circulates mainly complexed to cer-
uloplasmin (60–95%) and albumin (10 %) [3,4]. In cells, Cu is com-
plexed to metallochaperones including COX17 and ATOX1 [5] which
deliver Cu to cytochrome c and ATPase 7B respectively. Modifications
to Cu concentration and relative abundance of Cu isotopes (fractiona-
tion) have been linked to modified metabolic processes (oxidative
phosphorylation, hypoxia, angiogenesis), and thus to health and disease
[6].
Ovarian cancer diagnosis is currently based on circulating cancer
antigen 125 (CA-125) concentrations where it is elevated in 50 % of
early stage ovarian cancer cases [7], but is also increased in pregnancy,
endometriosis [8] and other benign clinical conditions, which reduces
its specificity. However it remains an effective approach for following
the response to chemotherapy on patients and detecting relapse [9].
To complement clinically available diagnostic methods, new bio-
markers including circulating tumour DNA, tumour serum proteins,
circulating cancer cells or serum levels of metals such as Cu and zinc
[10,11] are being developed due to increased sensitivity of multi col-
lector inductively coupled plasma-mass spectrometry (MC-ICP-MS).
Copper is present in the form of two ions Cu(I) and Cu(II) in cells
and in blood. Transport and uptake of these two Cu ions is the cause of
the selective distribution (fractionation) of the copper isotopes 63Cu(I/
II) and 65Cu(I/II) between the cells and the blood [6,12]. Recent studies
have measured a strong decrease of the ratio (δ65Cu, see Eq. 1) of Cu
isotopes in serum of breast or colorectal cancer patient [13].
The aims of the present study were to compare δ65Cu ratios i) from
whole blood in group of ovarian cancer patients compared to a healthy
control group and ii) evaluate a small series of ovarian cancer biopsies
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and healthy ovary tissue.
2. Material and methods
2.1. Clinical samples
Ethical approval for this study was obtained from NHS HRA Wales6
REC (15/WA/0065) to collect tissue and serum samples from ovarian
cancer patients and non-cancer controls. Formal written consent was
obtained from all patients at the time of recruitment into the study.
Patients attending general gynaecology clinics or gynaecology oncology
clinics in Swansea Bay and Cwm Taf Morgannwg NHS University
Health Boards (SBUHB and CTMUHB) were recruited into this study.
Forty-four women with histologically confirmed ovarian cancer were
recruited in this project. These were post-menopausal patients that
presented to primary care or emergency services with symptoms sug-
gestive of ovarian pathology (pain, abdominal bloating, weight loss and
change in bowel habit). An ovarian mass was subsequently identified on
imaging investigations (ultrasound, CT, MRI) and tumour marker
measurements [CA-125] performed. The histological evaluation of the
ovarian biopsies and the cancer diagnosis was confirmed by the
Pathology Department as part of the patient’s routine clinical care.
However, only patients with a confirmed ovarian tumour diagnosis
were included in the study. Patients with infection, chronic inflamma-
tion, autoimmune disease and other cancers were excluded from this
study. Amongst the patients, thirteen gave serum and biopsies and 31
gave only serum. Analysis of the CA-125 marker is reported in Table 1.
Women were between 43 and 83 years old with a mean of 64.4 years
old. Control serum (from the Etablissement Français du Sang, patient
agreement obtained through MTA13−1728) was obtained from women
between 19 and 65 years old with a mean of 33 years old were ana-
lysed. Data are included in supplementary 1 (Télouk et al., submitted to
Journal of Hepatology). Blood was sampled into dry test tubes, cen-
trifuged immediately, and stored at −80 °C. Two hundred microliters
of serum were mineralized on a hot plate in a mixture of 2 mL of nitric
acid and 0.5 mL of hydrogen peroxide and processed on a macroporous
anion-exchange resin AGMP1 100–200 mesh (Biorad, UK) to separate
Cu [14]. Biopsies (Table 2) placed into culture medium at the time of
surgery were cut in pieces and one piece retained for isotopic mea-
surements. These pieces were weighed and mineralized on a hot plate in
a mixture of 2 mL nitric acid and 0.5 mL hydrogen peroxide and pro-
cessed on a macroporous anion-exchange resin to separate Cu.
2.2. Spectrometry
Element concentrations were determined as previously described
[14,15] by ICP-MS using an iCAP Q (Thermofisher Scientific, Bremen,
Germany). 65Cu/63Cu ratios of the blood and biopsy samples were de-
termined using a Nu instrument multiple-collector inductively coupled
plasma mass spectrometer (MC-ICP-MS) Nu Plasma HR 500 (Wrexham,
UK). As mass spectrometry isotopic measurement by MC-ICP-MS suffers
from a stable bias between samples, a correction was systematically
applied. For this, a constant and known standard made of zinc was
systematically added in the purified samples. The Zinc acts as a mass
bias corrector and standard in sample bracketing as it is measured at the
same time as copper and is used as reference. This allow to reduce the
MC-ICP-MS mass bias inducing wrong measurement compared to the
real isotopic composition in copper.
A conventional delta value δ65Cu is used throughout to report the
Cu isotope abundances. δ65Cu is a dimensionless parameter defined as:
∂ = ⎡
⎣⎢
⎤
⎦⎥
× −Cu Cu Cu Cu Cu
Cu Cu
θ( / )sample-( / )ref
( / )ref
10 sin65
65 63 65 63
65 63
3 1
(1)
This represents the relative deviation of the 65Cu/63Cu ratio in the
measured sample from its value in the reference material NIST SRM 976
in parts per 1000 (‰). Typical reproducibility on δ65Cu at the 95
percent confidence level as determined from three replicates of serum
samples is 0.05‰. Natural variations of δ65Cu in inorganic and organic
material do not exceed +/- 3‰ [16]. These δCu variations are due to
metabolic processes and biological variability.
3. Statistical analysis
Normality of the data was analysed using a Kolmogorov Smirnov
test.
Statistically significant differences on δCu values between healthy
serum vs OC serum samples were assessed using a 2-samples t-test as
distributions of the datasets were normal. Statistically significant dif-
ferences on δCu values between tumour vs non tumour ovarian biopsies
were assessed using a Mann Whitney test as distributions of the datasets
were not normal.
In order to evaluate the correlation between age and δCu of ovarian
cancer patients, as the datasets were normally distributed we undertook
a Pearson’s Correlation Test. In order to evaluate the differences be-
tween number of chemotherapy and δ65Cu values, we performed a
Mann-Whitney test between the different groups we described in the
results. Finally, the differences between cancer stage and δ65Cu values
was assessed using a Kruskal Wallis test between the different groups
described in the results.
4. Results
4.1. Clinical diagnosis and treatment
Forty-four ovarian cancer patients were included in this study and
results compared to data from 48 healthy patients (See Supplementary
1. Télouk et al. unpublished). The mean age of the women with ovarian
cancer in the study was 64.4 years, and women were post-menopause
(Table 1). In total 22 women were diagnosed with FIGO (Federation
Internationale de Gynécologie et d’Obstétrique) stage 3 ovarian cancer,
seven with FIGO stage 4 cancer and 8 FIGO stage 1 or 2 and seven
benign masses.
We obtained ovarian biopsy samples from 13 patients from one or
from both ovaries, 11 were tumoral and 10 were non tumoral (Table 2).
The 13 patient cohort included those diagnosed with high grade serous
ovarian cancer (HGSOC) (n = 6), borderline ovarian tumour (n = 1),
endometrioid ovarian adenocarcinoma (n = 2) and benign tumour
masses (n = 4). The levels of CA-125 were measured at diagnosis.
Patients presenting before Pt chemotherapy had high levels of the
marker (mean of the group = 1301±1370). The effect of Pt treatment
was followed by monitoring CA-125 levels. Samples were taken when
the marker had significantly decreased (mean of the group =
205±250).
4.2. Association between δ65Cu and cancer
Healthy patient serum δ65Cu values were compared to that of
ovarian cancer patients (Fig. 1). Ovarian cancer patient serums had a
copper isotope ratio ranging from -1.59 to -0.14‰ (median -0.80‰,
mean -0.78‰±0.05), a distribution that was significantly lower
(p< 0.001) than the control group (between -0.71 and 0.05‰, median
-0.23‰, mean -0.23‰±0.02). Comparison of the copper isotope ratio
in eleven ovarian tumour biopsies and ten non-tumour ovarian biopsies
showed that in tumour biopsies, δ65Cu values were between -0.19 and
0.59‰ (n = 11, median -0.09‰, mean 0.09‰±0.08). δ65Cu values
were significantly lower (p< 0.05) in healthy ovaries with values
ranging from -0.63 to 0.08‰ (n = 10, median of -0.16‰, mean of
-0.16‰±0.06 p< 0.05). Finally, no difference was found between
δ65Cu of the 13 patients we obtained serum and biopsies from and the
31 patients with only serum samples (p>0.05).
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4.3. Association between δ65Cu and cancer status
Serum δ65Cu values were compared based on stage of the cancer
disease. Using a Kruskal Wallis test, no association was found between
cancer stage and δ65Cu in blood, with a median of -0.58‰ (mean
-0.61‰±0.10) for stage 4, -0.83‰ (mean -0.86‰±0.07) for stage 3,
-0.87‰ (mean -0.79‰±0.08) for stage 2 and -0.80‰ (mean
-0.72‰±0.12) for stage 1 patients (p = 0.95). Moreover, no asso-
ciation was found between stage in the disease and δ65Cu in tumour
mass. The low number of tumour mass samples from stage 4 patients
may explain the lack of correlation.
The number of cycles of chemotherapy appeared to influence the
δ65Cu value in the biopsies. Patients receiving at least four cycles of
chemotherapy had a significantly (p = 0.05) higher δ65Cu (n = 6,
median = -0.01, mean = 0.12‰±0.08) than patients receiving no
chemotherapy (n = 7, median = -0.10, mean = -0.15‰±0.06).
Finally we decided to evaluate if the differences on δ65Cu levels
between patients were dependent on the patients age at the time of
sample collection using a Pearson’s Correlation Test. No significant
association was observed between the patient’s age and δ65Cu (p-value
= 0,115, r= -0272).
5. Discussion
In the present study the degree of copper fractionation was mea-
sured in blood and tissue samples obtained from ovarian cancer pa-
tients, and δ65Cu was used to determine the ratio of the two stable
copper isotopes. A positive δ65Cu indicated depletion of circulating
63Cu isotope, possibly due to an uptake by tumour cells, and conversely
a negative value indicated an enrichment of the lighter 63Cu isotope in
serum. We observed that δ65Cu was lower in the serum of ovarian
cancer patient compared to that from healthy donors. Thus, as in breast
and colorectal cancer [13], we observed that patients with ovarian
tumours have higher levels of 65Cu in the tumour mass than in blood.
No correlation was made between the stage of cancer and serum δ65Cu.
Thus, whilst δ65Cu correlates with ovarian cancer diagnosis it displays
no specificity for cancer type or stage [13,17].
The mechanism behind the decrease of δ65Cu in the serum of cancer
patients has been suggested to be a consequence of the hypoxic tumour
environment that increases the relative level of lactate compared to
normal tissue and thus of an increased carboxyl group concentrations
available for complexation with Cu [13]. Since the heavy 65Cu copper
Cu(I) isotope forms more stable bonds with carboxyl groups of lactate
Table 1
Ovarian cancer: diagnostic, stage, number of cycles of chemotherapy and analytical data on serum samples (CS = Cancer Serum, *=pre-menopausal women, N/A =
not applicable, NC = non communicated).
Sample Number Age Cancer Diagnosis Stage Nb of chemotherapy Initial CA-125 at
diagnosis
CA-125 at recruitment in the
study
δCu(‰)
CS1 43 HGSOC 4A 3 1146 32 −0.25
CS2 57 HGSOC 4B 4 363 19 −0.98
CS3 73 Metastatic colorectal adenocarcinoma to the
ovaries
4B NC 202 202 −0.84
CS4 68 HGSOC 4A 3 >25,000 517 −0.57
CS5 71 HGSOC 4B 4 1857 21 −0.59
CS6 71 HGSOC 4B 6 4248 500 −0.47
CS7 76 HGSOC 4A 4 1656 35 −0.81
CS8 74 HGSOC 3C 3 198 53 −0.79
CS9 62 HGSOC 3C 3 3682 1154 −0.6
CS10 60 HGSOC 3C 6 3150 30 −0.87
CS11 50 HGSOC 3C 6 721 22 −1.36
CS12 82 HGSOC 3C 6 2085 57 −0.53
CS13 60 HGS Primary Peritoneal disease 3C 4 227 <6 −0.9
CS14 69 HGSOC 3C 6 796 20 −0.97
CS15 59 HGSOC 3C 6 11,450 59 −0.8
CS16 71 HGSOC 3C 5 423 14 −0.65
CS17 78 HGSOC 3C 9 2429 2227 −0.89
CS18 67 HGSOC 3C 6 81 19 −0.39
CS19 78 Ovarian Carcinosarcoma (Tubo) 3C None 160 160 −0.97
CS20 44 HGSOC 3C None 785 785 −0.67
CS21 55 Ovarian Carcinosarcoma 3C 3 831 122 −0.61
CS22 82 HGSOC 3C 4 836 155 −0.69
CS23 71 HGSOC 3C None 1161 1613 −1.22
CS24 83 HGSOC 3C 3 2538 206 −1.01
CS25 58 HGSOC 3C 4 634 231 −0.53
CS26 80 HGSOC 3C 4 58 35 −1.13
CS27 66 HGSOC 3C 6 340 35 −0.19
CS28 73 HGSOC 3C 4 204 37 −1.56
CS29 82 HGSOC 3C 4 634 231 −1.6
CS30 56 HGSOC 2C 4 302 24 −1.1
CS31 47 Endometrioid adenocarcinoma ovary 2A None 492 492 −0.14
CS32 62 Ovarian Clear Cell 1C2 None 241 431 −0.82
CS33 67 Ovarian Granulosa cell tumour 1C2 None 38 38 −0.98
CS34 68 Ovarian Borderline Serous Cystadenoma 1C2 None 37 18 −0.68
CS35 54 Endometrioid adenocarcinoma ovary 1A None 74 74 −0.53
CS36 57 Borderline Serous Carcinoma 1A None 67 67 −0.91
CS37 60 Borderline Ovarian Serous tumour 1A None 64 52 −0.84
CS38 60 Ovarian Fibroma Benign N/A 55 68 −0.49
CS39 55 Mucinous Cystadenoma Benign N/A 54 54 −1.05
CS40 51 Ovarian Fibroma Benign N/A 73 64 −0.76
CS41 64 Ovarian Fibroma Benign N/A 13 13 −1.17
CS42 51 Mucinous Cystadenoma Benign N/A 52 52 −0.16
CS43 46 HGSOC N/A None 12 12 −0.93
CS44 74 Ovarian Fibroma Benign N/A 37 37 −0.38
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than lighter Cu isotopes it would be preferentially chelated and thus
retained in cancer cells, resulting in an apparent decrease of serum
δ65Cu [17]. In cells, copper is present predominantly as Cu(I) and is
always complexed with transport proteins to overcome its reactivity,
therefore avoiding the production of reactive oxygen species that can
cause cellular damage. Ab initio calculations on the ability of organic
molecules to coordinate with copper have been undertaken [18,19]. O
donor (glutamine, threonine), N donor (histidine) and S donor (cy-
steine, methionine) amino acids19] were found to be preferentially
bind 63Cu light copper isotopes of Cu(II), and can also be assumed to
fractionate as Cu(I) [20].
In ovarian cancer, patients often relapse following an initial positive
response to platinum chemotherapy, developing resistance and thus
reducing subsequent therapeutic options [9]. The most common
mechanisms for resistance are the overexpression of ATP-dependent
efflux pumps such as MDR1 and ATPases 7A and B [21,22]. The ATP-
dependent copper transporter ATPases 7A and 7B supplies the Golgi
with copper needed for enzyme synthesis. While ATPases 7A and 7B
allows fine control of copper concentration in cells, its activity also
allows tumour cells to detoxify platinum-based drugs which increase
the resistance of the cells to treatment [23–25]. It seems likely therefore
that copper fractionation in ovarian cancer following chemotherapy
could occur due to the overexpression of ATP7ase A drug efflux pump
[26,27] to detoxify Pt treated patients (Fig. 2). This is supported by our
mass spectrometric analysis that revealed a decrease in the δ65Cu value
in ovarian cancer patients corresponding to a decrease in circulating
65Cu in these patients (δ65Cu=-0.80‰), and an increase δ65Cu value in
tumours (δ65Cu=-0.01‰) compared to healthy tissue.
Table 2
Ovarian cancer: diagnostic, stage, number of cycle of chemotherapy and analytical data on biopsy samples (CB = Cancer biopsy, *=pre-menopausal women, N/A =
not applicable).
Sample Number Age Cancer Diagnosis Stage Nb of
chemotherapy
Tumour δCu
(‰)
Non Tumour
δCu(‰)
Comments
CB6 Right 71 HGSOC 4B 6 −0.09 HGSOC
Left HGSOC 0.01 HGSOC
CB17 Right 78 HGSOC 3C 9 0.33 HGSOC
Left Not sampled
CB18 Right 67 HGSC of L fallopian tube 3C 6 −0.06 Benign
Left 0.26 Benign
CB25 Right 58 HGSOC 3C 4 0.57 HGSOC
Left 0.59 HGSOC
CB27 Right 66 HGSC of L fallopian tube 3C 6 −0.13 HGSOC
Left −0.11 HGSOC
CB28 Right 73 HGSC of L fallopian tube 3 4 −0.28 Benign
Left 0.29 HGSOC
CB31 Right 47 Grade 3 endometrioid type 2A None −0.09 Normal
Left Endometrioid adenocarcinoma
CB34 Right 68 Borderline R Ovarian serous
cystadenoma
1C2 None −0.09 Borderline R Ovarian serous cystadenoma
Left 0.08 Several serous inclusion cysts
CB35 Right 54 L Ovarian endometrioid
adenocarcinoma
1A None −0.02 Endometriosis foci
Left Endometrioid adenocarcinoma with big
endometriosis and cystadenoma
CB39 Right 55 Benign L mucinous cystadenoma Not cancer N/A −0.22 Normal
Left −0.26 Benign L mucinous cystadenoma
CB41 Right 64 Benign R fibroma Not cancer N/A Benign R fibroma
Left 0.06 Normal
CB42 Right 51 Benign R mucinous cystadenoma Not cancer N/A −0.22 Benign mucinous cystadenoma
Left Normal
CB43 Right 46 Leiomyosarcoma favoured to be
of broad ligament origin
N/A None −0.63 Cellular spindle cell tumour with fascicular
growth pattern w/ moderate to severe atypia
Left −0.11 Normal
Fig. 1. Comparison of δ65Cu between healthy blood donor and ovarian cancer blood and between ovarian cancer mass and non-tumour ovarian biopsy.
A) Whisker plot of serum δ65Cu values for healthy women (48) compared to ovarian cancer patients (44). Boxes represent the 75 percent middle quantile and the
whiskers 95 percent quantiles. Horizontal line: median. Separation between ovarian cancer patients and healthy women is significant (p< 0.001).
B) Whisker plot of 11 ovarian cancer mass and 10 contra-lateral ovaries that are either healthy either withdraw to be checked for cancer development. Significant
difference has been measured between the two conditions (p< 0.05).
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6. Conclusion
Here we have demonstrated that Cu serum δ65Cu levels are lower in
ovarian cancer patients than in healthy donors. Conversely, ovarian
cancer biopsies display a higher δ65Cu than serum from healthy vo-
lunteers. Our study highlights the potential of Cu as a functional bio-
marker for the detection of ovarian cancer. Current development of new
automatized tools to perform the chemistry on biological samples and
increased performance of measurement of MC-ICP-MS will allow the
future implementation of δ65Cu to aid ovarian cancer detection when
CA-125 and other imaging techniques are not conclusive. A larger
clinical study is now required to define δ65Cu thresholds that would be
indicative of the presence of the disease.
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Fig. 2. Proposed mechanisms of copper fractionation
between normal cells and platinum treated cancer
cells.
Changes in the circulating 65Cu levels from patients
who have received chemotherapy may be multi-
factorial. The tumour environment is hypoxic and re-
sults in an increase in tumour cellular lactate meta-
bolism leading to the preferentially chelation of heavy
copper by lactate thus retaining this isoform of Cu in
the tumour cells. In addition, selectivity of copper
transporter toward light copper isotopes 63Cu occurs
due to transporter amino acid sequence composition
[20]. In platinum treated cancer cells the copper
transporter ATP7A would selectively export 63Cu. This
would result in 65Cu being selectively retained in the
tumour cells by lactate and increased expression of
efflux copper transporter increasing the relative
amount of 63Cu in blood.
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